- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04708925
Hypertriglyceridemia-associated Acute Pancreatitis: Apheresis Vs. Conservative Treatment
Hypertriglyceridemia-associated Acute Pancreatitis: Apheresis Vs. Conservative Treatment. A Retrospective Study
Introduction: Hypertriglyceridemia is one of the etiologies of acute pancreatitis. It may cause severe multi-system disease resulting in high morbidity and mortality. There is controversy regarding the best method to treat it, which includes, among other therapies, high-dose insulin and performing plasma exchange (apheresis).
Aims: Primary outcome - Comparison of 28- day mortality between hypertriglyceridemia-induced acute pancreatitis patients who received conservative therapy versus those who received apheresis therapy. Secondary outcomes: Comparison of morbidity parameters and rate of blood triglycerides level decrease between the groups.
Materials and Methods: A retrospective study based on observational data collection, which will include all patients aged 18--99 who were admitted to the intensive care unit in 2010-2020 in the diagnosis of acute pancreatitis secondary to high blood lipids. Data will be collected from hospital files and computerized systems. Data will include demographics, admission times, ventilation days, pressor support, 28- day mortality,daily triglyceride level, medical history, APACHE-2 score, lactate level, need for dialysis, need for antibiotics and surgical intervention. The study will include 29 patients. All demographic and patient parameters will be statistically examined by a qualified statistician depending on the type of data.
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Background: Hypertriglyceridemia causes 1-7% of all acute pancreatitis cases. The mechanism by which excess lipids in the blood cause pancreatitis is not entirely clear. The hypothesis is, that the enzyme lipase, which originates in the pancreas, causes increased breakdown of triglycerides into free fatty acids, which are toxic to endothelial cells and pancreatic acinary cells. In addition, excess fat in the blood increases blood viscosity and impairs blood flow to the pancreas, thus causing necrosis.
There is controversy regarding the best way to treat pancreatitis secondary to hypertriglyceridmia. In addition to fasting, intravenous fluids and analgesia, a number of methods have been used to lower blood lipids, such as heparin and insulin or plasma exchange. Performing plasma exchange causes rapid removal of lipids from the plasma, but it is not yet accepted as the treatment of choice, as there are so far no random prospective studies that have shown an advantage for this treatment method over conservative methods.
The American Society of apheresis defines plasma exchange as a Category 3 indication for the treatment of acute pancreatitis secondary to hyperlipidemia, i.e. as a treatment method whose effectiveness has not been unequivocally proven, and its use is at the discretion of the treating physician.
In the last ten years, the intensive care unit at our institution has treated 29 patients who were admitted due to hypertriglyceridemia induced acute pancreatitis. Some patients were treated conservatively, and some were treated by plasma exchange. We would like to investigate whether there was a difference in mortality rates and morbidity parameters between the groups.
Aims: The primary outcome of this study was to compare 28-days mortality rates among patients who received apheresis versus those who did not. Secondary outcomes were comparison of morbidity parameters between the groups: APACHE score, ICU and hospital length of stay, ventilation days, pressor support, need for renal replacement therapy, need for antibiotics, need for surgical of minimally invasive intervention, and rate of blood triglycerides decrease.
Materials and methods: A retrospective study among patients who were admitted to the ICU between years 2010-2020 due to hypertriglyceridemia-induced acute pancreatitis, a total of 29 cases. Data will be collected from hospital files and computer systems (Chameleon system and iMDsoft software).
Inclusion criteria: All patients aged 18-99 who were admitted to the intensive care unit in Meir medical hospital between years 2010-2020, whose cause of admission was hypertriglyceridemia-induced acute pancreatitis, defined as abdominal pain, elevated levels of amylase and lipase and blood triglyceride level above 1000 mg/dl, without any other apparent etiology of pancreatitis.
Collected data: Patient demographics and medical history including chronic pharmacologic therapy, hospital admission times, ventilation days, inotropic therapy, hemodialysis, daily blood triglyceride level, 28-day mortality, APACHE 2 score, lactate level, antibiotic therapy and need for surgical intervention. All data will be statistically analyzed according to type of data
Study Type
Enrollment (Actual)
Contacts and Locations
Study Locations
-
-
-
Kfar Saba, Israel
- Meir Medical Center
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
All patients aged 18-99 who were admitted to the intensive care unit in Meir medical hospital between years 2010-2020, whose cause of admission was hypertriglyceridemia-induced acute pancreatitis, defined as abdominal pain, elevated levels of amylase and lipase and blood triglyceride level above 1000 mg/dl, without any other apparent etiology of pancreatitis.
-
Description
Inclusion Criteria:All patients aged 18-99 who were admitted to the intensive care unit in Meir medical hospital between years 2010-2020, whose cause of admission was hypertriglyceridemia-induced acute pancreatitis, defined as abdominal pain, elevated levels of amylase and lipase and blood triglyceride level above 1000 mg/dl, without any other apparent etiology of pancreatitis.
-
Exclusion Criteria:None
-
Study Plan
How is the study designed?
Design Details
- Observational Models: Other
- Time Perspectives: Retrospective
Cohorts and Interventions
Group / Cohort |
Intervention / Treatment |
---|---|
group A- conservative therpay
hypertriglyceridemia-induced acute pancreatitis patients who recieved conservative therapy
|
|
group B- plasmapharesis therapy
hypertriglyceridemia-induced acute pancreatitis patients who recieved plasmapharesis therapy
|
conservative versus plasmapharesis therapy
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
28-day mortality
Time Frame: 28 days
|
mortality within 28 days from ICU admission
|
28 days
|
Collaborators and Investigators
Sponsor
Investigators
- Study Chair: Sara Dichtwald, MD, Meir Medical Center
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 0350-19-MMC
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Acute Pancreatitis
-
Centre Hospitalier Universitaire de NiceRecruiting
-
John Gasdal KarstensenCompleted
-
Tianjin Nankai HospitalCompletedAcute PancreatitisChina
-
Mayo ClinicNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)CompletedAcute Pancreatitis (AP) | Gallstone Pancreatitis | Alcoholic Pancreatitis | Trauma Acute Pancreatitis | Hypertriglyceridemia Acute Pancreatitis | Idiopathic (Unknown) Acute Pancreatitis | Medication Induced Acute Pancreatitis | Cancer Acute Pancreatitis | Miscellaneous (i.e. Acute on Chronic Pancreatitis)United States
-
Northern State Medical UniversityCompleted
-
Erzhen ChenRenJi HospitalUnknownPancreatitis,Acute NecrotizingChina
-
Orlando Health, Inc.Mayo Clinic; University of Alabama at Birmingham; University of Southern California and other collaboratorsActive, not recruitingPancreatitis,Acute NecrotizingUnited States
-
University of OuluCopenhagen University Hospital, HvidovreUnknownAcute Necrotizing PancreatitisFinland
-
Sichuan Academy of Medical SciencesPeking Union Medical College HospitalCompleted
-
Interscope, Inc.CompletedAcute Pancreatitis | Necrotizing Pancreatitis | Acute Pancreatic NecrosisUnited States, Netherlands, Germany
Clinical Trials on conservative versus plasmapharesis therapy
-
AO Clinical Investigation and Publishing DocumentationAOSpine North AmericaCompletedOdontoid Fractures Type IIUnited States
-
University Hospital, GenevaCentre Hospitalier Universitaire VaudoisUnknownIntestinal ObstructionSwitzerland
-
Maastricht Radiation OncologyUniversity of Pennsylvania; Philipps University Marburg Medical Center; University...CompletedCarcinoma, Squamous Cell of Head and NeckNetherlands
-
Assiut UniversityCompleted
-
University of PecsCompleted
-
University Hospital, Clermont-FerrandCompletedVertebrOpLasty Versus Conservative Treatment in Acute Non Osteoporotic Vertebral Fractures (VOLCANO)Vertebral Compression Fracture | Spinal TraumaFrance
-
Ministry of Health, MalaysiaUnknown
-
DermTechRecruitingAtopic DermatitisUnited States
-
Federal State Budget Institution Research Center...Sechenov UniversityCompletedThin EndometriumRussian Federation
-
Michael Wilson & Associates Health Care Consulting...Pneumex CorporationTerminatedLow Back Pain | RadiculopathyUnited States